First Epigenetic Silencer Shows Durable Hepatitis B Virus Suppression in Clinical Trial
TUNE-401 targets the hepatitis B viral reservoir using epigenetic silencing, offering the first clinical proof of a potential finite cure.
Summary
A biotech company called Tune Therapeutics has shared early clinical trial results for TUNE-401, a new treatment for chronic hepatitis B. Unlike current therapies that suppress the virus indefinitely, TUNE-401 aims to silence the viral DNA reservoir permanently using epigenetic tools — meaning it changes how genes are expressed without altering the DNA sequence itself. Delivered via lipid nanoparticles, the same technology used in mRNA vaccines, the drug targets cccDNA, the persistent viral blueprint that makes hepatitis B so hard to eliminate. Early Phase 1b/2a data show deep and lasting antiviral activity, raising hopes for a finite course of treatment rather than lifelong medication. Results will be formally presented at a major liver disease conference in May 2026.
Detailed Summary
Chronic hepatitis B affects roughly 300 million people worldwide and is a leading cause of liver cirrhosis and liver cancer — two conditions that dramatically shorten healthspan and lifespan. Current antiviral drugs suppress the virus but rarely eliminate it, requiring lifelong treatment. A genuine functional cure has remained elusive largely because of cccDNA, a circular viral DNA form that persists silently inside liver cells and continuously restocks the virus. Eliminating or permanently silencing cccDNA is considered the holy grail of hepatitis B research.
Tune Therapeutics has developed TUNE-401, a first-in-class epigenetic silencer designed specifically to target cccDNA. Rather than cutting or destroying the viral DNA, the drug uses epigenetic mechanisms to switch off its transcriptional activity — essentially placing a permanent chemical lock on the viral blueprint. The therapy is delivered using lipid nanoparticle technology provided by Acuitas Therapeutics, the same platform that enabled COVID-19 mRNA vaccines to reach cells efficiently.
Phase 1b/2a clinical trial results, described as late-breaking data, provide what the company calls the first clinical evidence that epigenetic silencing of cccDNA is achievable in humans. The data reportedly demonstrate deep and durable antiviral activity, suggesting the silencing effect persists after treatment ends — a critical requirement for any finite therapy.
For longevity-focused individuals, chronic hepatitis B represents a significant accelerant of liver aging, inflammation, and cancer risk. A finite cure would remove a major driver of premature mortality in hundreds of millions of people globally, with particular impact in Asia and sub-Saharan Africa.
Important caveats apply. This is early-phase data presented by the sponsoring company ahead of peer review. Full results, including safety profiles, durability timelines, and response rates, have not yet been independently published. The presentation at EASL 2026 on 30 May will offer the first detailed public disclosure.
Key Findings
- TUNE-401 is the first drug to show clinical evidence of epigenetic silencing of hepatitis B cccDNA reservoir.
- Early Phase 1b/2a data demonstrate deep and durable antiviral activity, supporting a finite treatment model.
- Lipid nanoparticle delivery — proven in mRNA vaccines — is used to transport the epigenetic silencer to liver cells.
- Epigenetic silencing switches off viral gene expression without altering the underlying DNA sequence.
- A finite hepatitis B cure could eliminate a major driver of liver cancer and cirrhosis-related premature death.
Methodology
This is a company-issued news report summarizing unpublished Phase 1b/2a clinical trial results ahead of a conference presentation. The source, Longevity.Technology, is a credible longevity-focused outlet, but the underlying data come from the sponsoring company and have not yet been peer-reviewed or independently verified.
Study Limitations
Data are company-reported and pre-publication, meaning independent peer review has not yet occurred. Full safety data, response rates, and durability endpoints are not disclosed in this summary. Longevity-relevant conclusions should be treated as preliminary until the complete trial results are published in a peer-reviewed journal.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.